Radiopharm Theranostics Initiates Phase 1 Trial for Novel Cancer Treatment

An announcement from Radiopharm Theranostics Limited ( (AU:RAD) ) is now available.

Radiopharm Theranostics Limited announced the dosing of the first patient in its Phase 1 ‘HEAT’ clinical trial of RAD 202, a proprietary nanobody targeting HER2-positive expression in advanced solid tumors. This milestone marks a significant step in the company’s transition to a clinical-stage entity and aims to address the unmet need for HER2-positive metastatic patients who are progressing or unable to tolerate current treatment options, potentially improving clinical outcomes while preserving quality of life.

The most recent analyst rating on (AU:RAD) stock is a Buy with a A$0.07 price target. To see the full list of analyst forecasts on Radiopharm Theranostics Limited stock, see the AU:RAD Stock Forecast page.

More about Radiopharm Theranostics Limited

Radiopharm Theranostics Limited is a clinical-stage biopharmaceutical company focused on developing innovative oncology radiopharmaceuticals for areas of high unmet medical need. The company is listed on ASX and NASDAQ and has a pipeline of distinct and highly differentiated platform technologies spanning peptides, small molecules, and monoclonal antibodies for use in cancer treatment.

Average Trading Volume: 6,012,841

Technical Sentiment Signal: Hold

Current Market Cap: A$65.35M

See more insights into RAD stock on TipRanks’ Stock Analysis page.